Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Menkes Disease

  • Author: Celia H Chang, MD; Chief Editor: Amy Kao, MD  more...
 
Updated: Oct 29, 2014
 

Background

Menkes disease, also known as kinky hair disease, is an X-linked neurodegenerative disease of impaired copper transport. Menkes et al first described it in 1962. Danks et al first noted that copper metabolism is abnormal in 1972; in 1973, after noting the similarity of kinky hair to the brittle wool of Australian sheep raised in areas with copper-deficient soil, he demonstrated abnormal levels of copper and ceruloplasmin in these patients.

A girl with the Menkes disease phenotype and an X:autosome chromosomal translocation was described in 1987, which led to the identification of the locus on the X chromosome in 1993. Milder variants of Menkes disease, including occipital horn syndrome (also known as X-linked cutis laxa or Ehlers-Danlos type 9) have also been described. The brindled mouse, viable brindled mouse, and blotchy mouse are animal models of the classic form, the mild form, and the occipital horn syndrome, respectively.

The image below depicts an infant with Menkes disease.

Four-month-old patient with classic Menkes disease Four-month-old patient with classic Menkes disease. His hair is depigmented and lusterless with pili torti and the skin is pale with eczema.

See 21 Hidden Clues to Diagnosing Nutritional Deficiencies, a Critical Images slideshow, to help identify clues to conditions associated with malnutrition.

Next

Pathophysiology

Copper is a trace metal in many essential enzyme systems, including cytochrome C oxidase, superoxide dismutase, lysyl oxidase, tyrosinase, ascorbic acid oxidase, ceruloplasmin, and dopamine beta hydroxylase. The deficiency or impaired function of these enzyme systems is thought to be responsible for the clinical findings of Menkes disease. The Menkes gene is located on the long arm of the X chromosome at Xq13.3, and the gene product (ATP7A) is a 1500–amino acid P-type adenosine triphosphatase (ATPase) that has 17 domains – 6 copper binding, 8 transmembrane, a phosphatase, a phosphorylation, and an ATP binding.

The Menkes and Wilson disease genes have 55% amino acid identity. Menkes and Wilson disease ATPases use common biochemical mechanisms, but the tissue-specific expression differs. The Wilson disease gene (WND) is expressed predominantly in the liver, whereas the Menkes disease gene (MNK) is not expressed in the liver. The predominant sites of Menkes gene expression are the placenta, GI tract, and blood-brain barrier. The Menkes protein is also in retinal pigment epithelial cells and the neurosensory retina.[1]

Hardman et al found that insulin and estrogen increased the level of MNK mRNA and protein levels in the placenta.[2] The MNK protein also became localized toward the basolateral membrane and increased copper transport. Hardman et al found levels of the Wilson disease ATPase decreased in response to insulin and was perinuclear. His conclusion was that the MNK protein delivers copper to the fetus and Wilson disease ATPase returns excess copper to the maternal circulation.

Niciu et al found that ATP7A is most abundant in the early postnatal period and peaks at P4 in the neocortex and cerebellum in the mouse brain.[3] ATP7A levels are highest in the ependymal cells of the lateral and third ventricles. ATP7A increases in CA2 hippocampal pyramidal and cerebellar Purkinje neurons but decreases in other cell populations postnatally. Schlief et al found that copper is protective and copper chelation exacerbates NMDA-mediated excitotoxic cell death in hippocampal neurons.[4]

All copper-transporting ATPases have a histidine residue in the large cytoplasmic loop adjacent to the ATP-binding domain. The histidine residue is the most common mutation site in Wilson disease, and this histidine residue is essential for the function of the Menkes ATPase, ATP7A. The Menkes protein is synthesized as a single-chain polypeptide localized to the trans-Golgi network in cells.

Under normal circumstances, ATP7A transports copper into the secretory pathway of the cell for incorporation into the cuproenzymes and excretion from the cell. An increase in intracellular copper causes ATP7A to move to the plasma membrane. As the copper is concentrated into vesicles for excretion from the cell, the cytosolic copper concentration decreases and ATP7A returns to the trans-Golgi network. The migration of ATP7A appears to involve amino acid sequences in the carboxyl terminus, utilizing both clathrin-dependent and clathrin-independent endocytosis. Menkes disease can be caused by both copper transport dysfunction and abnormal protein trafficking.

In Menkes disease, transport of dietary copper from intestinal cells is impaired, leading to the low serum copper levels. Abnormal copper transport in other cells leads to paradoxical copper accumulation in duodenal cells, kidney, pancreas, skeletal muscle, and placenta.

The Menkes gene product protein exists in both a truncated and a long form. The truncated form, which is located in the endoplasmic reticulum, is present in the occipital horn syndrome. The partial preservation of the copper transport-ATPase activity may account for the milder phenotype. Exon skipping is common in Menkes disease. Normal splicing of mRNA depends on a highly conserved, 9-nucleotide splice donor sequence. Slight variations from the splice donor sequence are common, except for the invariant GT (guanine-thiamine) dinucleotide at the +1 and +2 intronic positions. Splice acceptor sites have an invariant AG (adenine-guanine) dinucleotide at intronic positions -1 and -2. Splice junction mutations of the invariant bases severely reduce correct splicing. Patients with the milder Menkes phenotypes have mutations at other sites so that proper splicing of some protein still occurs.

Gross gene deletions occur in about 15% of patients, usually with the classic form of Menkes disease. The point mutations in ATP7A are 23% at the splice site, 20.7% nonsense, 17.2% missense, and 39.1% small deletions/insertions. Variable expression of an identical mutation can be present within a family.

Deficient cytochrome C oxidase (CCO) activity probably accounts for most of the neurologic symptoms, similar to patients with Leigh disease (subacute necrotizing encephalomyelopathy) who have reduced or absent CCO activity and similar neuropathologic changes. Linnebank et al found that copper supplementation in vitro helped to decrease homocysteine toxicity and preserved CCO activity.[5] Decreased lysyl oxidase (LO) activity accounts for the connective-tissue fragility and vascular abnormalities in Menkes disease, since LO deaminates lysine and hydroxylysine in the first step for collagen cross-linkage. LO localizes to the trans-Golgi network so subcutaneous injections of copper-histidine do not improve the activity of LO as the copper is not delivered into the Golgi apparatus. Tyrosinase deficiency (involved in melanin biosynthesis) most likely accounts for the hypopigmentation of the hair and skin seen in Menkes disease.

Purkinje cell loss is profound in Menkes disease. During development, the expression of ATP7A switches from Purkinje cells to Bergmann glia cells, which support Purkinje cell function in adults. ATP7A is a faster copper transporter and catalyses reactions faster than ATP7B, the deficient protein in Wilson disease. Peptidylglycine alpha-amidating mono-oxygenase (PAM) is necessary for the removal of the glycine residue from neuroendocrine precursors—corticotropin-releasing factor (CRH), thyrotropin-releasing hormone (TRH), calcitonin, and vasopressin. Deficiency of dopamine-beta-hydroxylase leads to reduced catecholamine levels. Decreased ascorbic acid oxidase activity leads to bone changes similar to those seen in scurvy.

Moller et al found that even a low level (2-5%) of normally spliced Menkes protein was sufficient to produce the milder occipital horn syndrome in one patient.[6] In contrast, the classic phenotype was seen in 2 patients with a similar mutation who did not produce any normal Menkes protein. Tang et al found that a novel occipital horn syndrome mutation (N1304S) was associated with approximately 30% residual function of ATP7A.[7]

Previous
Next

Etiology

Menkes disease is caused by mutations of the Xq13.3 gene (ATP7A).

Many of the gene defects are deletions that can be detected by Southern blot, but small duplications, nonsense mutations, and missense mutations have also been reported.

The mild variants of the disease in humans are generally caused by splicing defects.

Previous
Next

Epidemiology

In the United States, incidence is 1 in 50,000 to 1 in 250,000; one third of cases result from new mutations. A study in Japan from 1993-2003 found that Menkes disease incidence was 1 per 2.8 million live births and 4.9 per million male live births.

Menkes disease is an X-linked recessive condition and, therefore, usually affects boys through unaffected carrier women. The disease can be due to germ line mosaicism.

A few affected females with X: autosome translocations, X0/XX mosaicism, or unfavorable lyonization have been reported.

The onset of the classic form is in infancy. The milder variants have their onset in childhood or early adulthood.

Previous
Next

Prognosis

Most untreated patients with the classic form of Menkes disease die by age 3 years.

Kaler et al noted that infants who received treatment early (within 10 +/- 4 days) had a 92% survival after a median follow-up of 4.6 years. Historical controls that were diagnosed at 163 +/- 113 days and treated only had a 13% survival after a median follow-up of 1.8 years. In fact, 2 of their patients (one with a missense mutation and one with a splice junction alteration) who were treated within 10 days of life had normal neurodevelopmental outcomes at age 5 and 7. A child with the same mutation as the 5-year-old but treated later at 22 days of age did have neurologic sequelae but could walk with support and ride a tricycle. Patients with mutations that disrupt the translational reading frame or have a premature termination codon did not do as well. Their treatment regimen consisted of subcutaneous copper histidine injections of 250 micrograms twice a day to 1 year of age and then daily injections to 3 years of age.[10]

Tang et al also reported that 2 infants treated within 25 days of age had near normal neurodevelopment at 7 months and 3 years of age. However, another infant with an identical missense mutation who began treatment at 228 days of age remained at a 2- to 4-month neurodevelopmental level at a chronological age of 2.5 years. This mutation resulted in normal levels of ATP7A transcript, but the mutated protein had abnormally high posttranslational degradation.[7]

Paulsen et al caution that the biochemical profile needs to be examined as reinitiation of protein translation may ameliorate the effects of a large frameshift deletion with a premature termination codon.[15]

Donsante et al also reported that 3 untreated brothers had differing courses of their disease. The 2 older brothers had mild disease and were able to ambulate independently and did not have seizures. The youngest brother was more delayed and had epilepsy, but he also had a cardiac arrest as a neonate. The cardiac arrest may be the cause of the more severe problems in the youngest brother, but he also had lower serum copper levels and the highest DOPA:DHPG ratio. Furthermore, Donsante et al also reported 2 untreated brothers who had different courses. The older brother also had a milder course with the occipital horn phenotype but the younger brother had profound delay and epilepsy. The less affected sibling had higher ATP7A levels but it was not clear why. There was no somatic mosaicism detected in either family.[16]

Previous
 
 
Contributor Information and Disclosures
Author

Celia H Chang, MD Health Sciences Clinical Professor, Chief, Division of Child Neurology, Department of Neurology/MIND Institute, University of California, Davis, School of Medicine

Celia H Chang, MD is a member of the following medical societies: American Academy of Neurology, Child Neurology Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Kenneth J Mack, MD, PhD Senior Associate Consultant, Department of Child and Adolescent Neurology, Mayo Clinic

Kenneth J Mack, MD, PhD is a member of the following medical societies: American Academy of Neurology, Child Neurology Society, Phi Beta Kappa, Society for Neuroscience

Disclosure: Nothing to disclose.

Chief Editor

Amy Kao, MD Attending Neurologist, Children's National Medical Center

Amy Kao, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, Child Neurology Society

Disclosure: Have stock from Cellectar Biosciences; have stock from Varian medical systems; have stock from Express Scripts.

References
  1. Tumer Z, Moller LB. Menkes disease. Eur J Hum Genet. 2010 May. 18(5):511-8. [Medline]. [Full Text].

  2. Hardman B, Michalczyk A, Greenough M, et al. Hormonal regulation of the Menkes and Wilson copper-transporting ATPases in human placental Jeg-3 cells. Biochem J. 2007 Mar 1. 402(2):241-50. [Medline].

  3. Niciu MJ, Ma XM, El Meskini R, et al. Developmental changes in the expression of ATP7A during a critical period in postnatal neurodevelopment. Neuroscience. 2006. 139(3):947-64. [Medline].

  4. Schlief ML, West T, Craig AM, et al. Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity. Proc Natl Acad Sci U S A. 2006 Oct 3. 103(40):14919-24. [Medline].

  5. Linnebank M, Lutz H, Jarre E, et al. Binding of copper is a mechanism of homocysteine toxicity leading to COX deficiency and apoptosis in primary neurons, PC12 and SHSY-5Y cells. Neurobiol Dis. 2006 Sep. 23(3):725-30. [Medline].

  6. Moller LB, Tumer Z, Lund C, et al. Similar splice-site mutations of the ATP7A gene lead to different phenotypes: classical Menkes disease or occipital horn syndrome. Am J Hum Genet. 2000 Apr. 66(4):1211-20. [Medline].

  7. Tang J, Donsante A, Desai V, Patronas N, Kaler SG. Clinical outcomes in Menkes disease patients with a copper-responsive ATP7A mutation, G727R. Mol Genet Metab. 2008 Nov. 95(3):174-81. [Medline].

  8. Bahi-Buisson N, Kaminska A, Nabbout R, et al. Epilepsy in Menkes disease: analysis of clinical stages. Epilepsia. 2006 Feb. 47(2):380-6. [Medline].

  9. Prasad AN, Levin S, Rupar CA, Prasad C. Menkes disease and infantile epilepsy. Brain Dev. 2011 Nov. 33(10):866-76. [Medline].

  10. Kaler SG, Holmes CS, Goldstein DS, et al. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med. 2008 Feb 7. 358(6):605-14. [Medline].

  11. Matsuo M, Tasaki R, Kodama H, Hamasaki Y. Screening for Menkes disease using the urine HVA/VMA ratio. J Inherit Metab Dis. 2005. 28(1):89-93. [Medline].

  12. Lee ES, Ryoo JW, Choi DS, Cho JM, Kwon SH, Shin HS. Diffusion-weighted MR imaging of unusual white matter lesion in a patient with Menkes disease. Korean J Radiol. 2007 Jan-Feb. 8(1):82-5. [Medline]. [Full Text].

  13. Geller TJ, Pan Y, Martin DS. Early neuroradiologic evidence of degeneration in Menkes' disease. Pediatr Neurol. 1997 Oct. 17(3):255-8. [Medline].

  14. Sheela SR, Latha M, Liu P, et al. Copper-replacement treatment for symptomatic Menkes disease: ethical considerations. Clin Genet. 2005 Sep. 68(3):278-83. [Medline].

  15. Paulsen M, Lund C, Akram Z, Winther JR, Horn N, Moller LB. Evidence that translation reinitiation leads to a partially functional Menkes protein containing two copper-binding sites. Am J Hum Genet. 2006 Aug. 79(2):214-29. [Medline].

  16. Donsante A, Tang J, Godwin SC, et al. Differences in ATP7A gene expression underlie intrafamilial variability in Menkes disease/occipital horn syndrome. J Med Genet. 2007 Aug. 44(8):492-7. [Medline].

  17. Adaletli I, Omeroglu A, Kurugoglu S, Elicevik M, Cantasdemir M, Numan F. Lumbar and iliac artery aneurysms in Menkes' disease: endovascular cover stent treatment of the lumbar artery aneurysm. Pediatr Radiol. 2005 Oct. 35(10):1006-9. [Medline].

  18. Ambrosini L, Mercer JF. Defective copper-induced trafficking and localization of the Menkes protein in patients with mild and copper-treated classical Menkes disease. Hum Mol Genet. 1999 Aug. 8(8):1547-55. [Medline].

  19. Aoki T. Wilson's disease and Menkes disease. Pediatr Int. 1999 Aug. 41(4):403-4. [Medline].

  20. Barnes N, Tsivkovskii R, Tsivkovskaia N, Lutsenko S. The copper-transporting ATPases, Menkes and Wilson disease proteins, have distinct roles in adult and developing cerebellum. J Biol Chem. 2005 Mar 11. 280(10):9640-5. [Medline].

  21. Borm B, Moller LB, Hausser I, et al. Variable clinical expression of an identical mutation in the ATP7A gene for Menkes disease/occipital horn syndrome in three affected males in a single family. J Pediatr. 2004 Jul. 145(1):119-21. [Medline].

  22. Ferreira RC, Heckenlively JR, Menkes JH, Bateman JB. Menkes disease. New ocular and electroretinographic findings. Ophthalmology. 1998 Jun. 105(6):1076-8. [Medline].

  23. Gasch AT, Kaler SG, Kaiser-Kupfer M. Menkes disease. Ophthalmology. 1999 Mar. 106(3):442-3. [Medline].

  24. Gerard-Blanluet M, Birk-Moller L, Caubel I, et al. Early development of occipital horns in a classical Menkes patient. Am J Med Genet A. 2004 Oct 1. 130(2):211-3. [Medline].

  25. Godwin SC, Shawker T, Chang B, Kaler SG. Brachial artery aneurysms in Menkes disease. J Pediatr. 2006 Sep. 149(3):412-5. [Medline].

  26. Goodyer ID, Jones EE, Monaco AP, Francis MJ. Characterization of the Menkes protein copper-binding domains and their role in copper-induced protein relocalization. Hum Mol Genet. 1999 Aug. 8(8):1473-8. [Medline].

  27. Grange DK, Kaler SG, Albers GM, et al. Severe bilateral panlobular emphysema and pulmonary arterial hypoplasia: unusual manifestations of Menkes disease. Am J Med Genet A. 2005 Dec 1. 139(2):151-5. [Medline].

  28. Gu YH, Kodama H, Shiga K, et al. A survey of Japanese patients with Menkes disease from 1990 to 2003: incidence and early signs before typical symptomatic onset, pointing the way to earlier diagnosis. J Inherit Metab Dis. 2005. 28(4):473-8. [Medline].

  29. Hsi G, Cox DW. A comparison of the mutation spectra of Menkes disease and Wilson disease. Hum Genet. 2004 Jan. 114(2):165-72. [Medline].

  30. Kaler SG. Metabolic and molecular bases of Menkes disease and occipital horn syndrome. Pediatr Dev Pathol. 1998 Jan-Feb. 1(1):85-98. [Medline].

  31. Kim BE, Smith K, Petris MJ. A copper treatable Menkes disease mutation associated with defective trafficking of a functional Menkes copper ATPase. J Med Genet. 2003 Apr. 40(4):290-5. [Medline].

  32. Kim OH, Suh JH. Intracranial and extracranial MR angiography in Menkes disease. Pediatr Radiol. 1997 Oct. 27(10):782-4. [Medline].

  33. Kodama H, Gu YH, Mizunuma M. Drug targets in Menkes disease - prospective developments. Expert Opin Ther Targets. 2001 Oct. 5(5):625-635. [Medline].

  34. Kodama H, Murata Y. Molecular genetics and pathophysiology of Menkes disease. Pediatr Int. 1999 Aug. 41(4):430-5. [Medline].

  35. Kodama H, Murata Y, Kobayashi M. Clinical manifestations and treatment of Menkes disease and its variants. Pediatr Int. 1999 Aug. 41(4):423-9. [Medline].

  36. Kodama H, Sato E, Yanagawa Y, et al. Biochemical indicator for evaluation of connective tissue abnormalities in Menkes' disease. J Pediatr. 2003 Jun. 142(6):726-8. [Medline].

  37. Krajacic P, Qian Y, Hahn P, et al. Retinal localization and copper-dependent relocalization of the Wilson and Menkes disease proteins. Invest Ophthalmol Vis Sci. 2006 Jul. 47(7):3129-34. [Medline].

  38. Lane C, Petris MJ, Benmerah A, et al. Studies on endocytic mechanisms of the Menkes copper-translocating P-type ATPase (ATP7A; MNK). Endocytosis of the Menkes protein. Biometals. 2004 Feb. 17(1):87-98. [Medline].

  39. Mandelstam SA, Fisher R. Menkes disease: a rare cause of bilateral inguinal hernias. Australas Radiol. 2005 Apr. 49(2):192-5. [Medline].

  40. Menkes JH. Menkes disease and Wilson disease: two sides of the same copper coin. Part I: Menkes disease. Eur J Paediatr Neurol. 1999. 3(4):147-58. [Medline].

  41. Mercer JF, Ambrosini L, Horton S, et al. Animal models of Menkes disease. Adv Exp Med Biol. 1999. 448:97-108. [Medline].

  42. Munakata M, Sakamoto O, Kitamura T, et al. The effects of copper-histidine therapy on brain metabolism in a patient with Menkes disease: a proton magnetic resonance spectroscopic study. Brain Dev. 2005 Jun. 27(4):297-300. [Medline].

  43. Muz' NI, Matvienko AV. [Local injection of fraxiparine for the treatment of the lower extremity trophic ulcer]. Klin Khir. 2002 Nov-Dec. 51-2. [Medline].

  44. Online Mendelian Inheritance in Man, OMIM (TM). Johns Hopkins University, Baltimore, MD. MIM Number: 309400. [Full Text].

  45. Pedespan JM, Jouaville LS, Cances C, et al. Menkes disease: study of the mitochondrial respiratory chain in three cases. Eur J Paediatr Neurol. 1999. 3(4):167-70. [Medline].

  46. Petris MJ, Mercer JF. The Menkes protein (ATP7A; MNK) cycles via the plasma membrane both in basal and elevated extracellular copper using a C-terminal di-leucine endocytic signal. Hum Mol Genet. 1999 Oct. 8(11):2107-15. [Medline].

  47. Petris MJ, Mercer JF, Camakaris J. The cell biology of the Menkes disease protein. Adv Exp Med Biol. 1999. 448:53-66. [Medline].

  48. Poulsen L, Moller LB, Plunkett K, et al. X-linked Menkes disease: first documented report of germ-line mosaicism. Genet Test. 2004. 8(3):286-91. [Medline].

  49. Sasaki G, Ishii T, Sato S, et al. Multiple polypoid masses in the gastrointestinal tract in patient with Menkes disease on copper-histidinate therapy. Eur J Pediatr. 2004 Dec. 163(12):745-6. [Medline].

  50. Suzuki M, Gitlin JD. Intracellular localization of the Menkes and Wilson's disease proteins and their role in intracellular copper transport. Pediatr Int. 1999 Aug. 41(4):436-42. [Medline].

  51. Tang J, Robertson S, Lem KE, et al. Functional copper transport explains neurologic sparing in occipital horn syndrome. Genet Med. 2006 Nov. 8(11):711-8. [Medline].

  52. Tumer Z, Birk Moller L, Horn N. Screening of 383 unrelated patients affected with Menkes disease and finding of 57 gross deletions in ATP7A. Hum Mutat. 2003 Dec. 22(6):457-64. [Medline].

  53. Tumer Z, Moller LB, Horn N. Mutation spectrum of ATP7A, the gene defective in Menkes disease. Adv Exp Med Biol. 1999. 448:83-95. [Medline].

  54. Waggoner DJ, Bartnikas TB, Gitlin JD. The role of copper in neurodegenerative disease. Neurobiol Dis. 1999 Aug. 6(4):221-30. [Medline].

  55. Zaffanello M, Fanos V. Rare urological abnormalities in 2 cases of Menkes' syndrome. J Urol. 2003 Oct. 170(4 Pt 1):1335. [Medline].

  56. Gu YH, Kodama H, Ogawa E, Izumi Y. Lactate and pyruvate levels in blood and cerebrospinal fluid in patients with Menkes disease. J Pediatr. 2014 Apr. 164(4):890-4. [Medline].

 
Previous
Next
 
Four-month-old patient with classic Menkes disease. His hair is depigmented and lusterless with pili torti and the skin is pale with eczema.
Diverticula of the bladder in a boy with Menkes disease.
The clavicles are short with hammer-shaped distal ends in a patient with Menkes disease.
Flared metaphyses of the ulna and radius in a 5-month-old patient with classic Menkes disease.
Lax skin in a patient with occipital horn syndrome.
Occipital horns (arrow) in a 14-year-old boy with occipital horn syndrome.
Magnetic resonance imaging of the brain of a patient with Menkes disease. Subdural effusion is evident in the left frontal lesion. Brain atrophy is also evident.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.